Table 1.
Baseline Characteristics
| Characteristic | SPIROMICS Participants With COPD and Complete Data |
Matched Participants:Longitudinal Analysis, Whole Follow-up Period |
||||
|---|---|---|---|---|---|---|
| Daily Aspirin Users (n = 764) | Aspirin Nonusers (n = 934) | P Value | Daily Aspirin Users (n = 503) | Aspirin Nonusers (n = 503) | P Value | |
| Age, mean ± SD | 67.5 ± 6.8 | 63.5 ± 8.4 | < .0001 | 66.5 ± 6.8 | 66.5 ± 7.6 | 1 |
| Female | 270 (35.3) | 450 (48.2) | < .0001 | 210 (41.8) | 208 (41.4) | .9 |
| Race: black | 80 (10.5) | 167 (17.9) | < .0001 | 63 (12.5) | 60 (11.9) | .8 |
| Less than high school education | 267 (35) | 386 (41.3) | .007 | 189 (37.6) | 196 (39) | .6 |
| FEV1 % predicted (postbronchodilator) | 63.1 ± 22.6 | 59.7 ± 23.2 | .003 | 62.4 ± 23.2 | 61.7 ± 22.9 | .7 |
| Current smoker | 206 (27) | 363 (38.9) | < .0001 | 155 (30.8) | 150 (29.8) | .7 |
| Cigarettes/d among current smokers, median (Q1-Q3) | 12 (6-20) | 15 (8-20) | .05 | 10.5 (6-20) | 15 (7-20) | .2 |
| Supplemental home oxygen | 182 (23.8) | 212 (22.7) | .6 | 115 (22.9) | 118 (23.5) | .8 |
| Percent emphysema on MDCT scan, mean ± SD | 10.5 ± 10.7 | 11.8 ± 11.8 | .02 | 11.0 ± 11.4 | 10.6 ± 10.7 | .5 |
| Emphysema ≥ 5% on MDCT scan | 423 (55.9) | 549 (59) | .2 | 282 (56.3) | 280 (55.9) | .9 |
| Anemia: hemoglobin < 13 g/dL (males) or < 12 g/dL (females) | 84 (11) | 69 (7.4) | .01 | 41 (8.2) | 52 (10.3) | .2 |
| Hypertension | 477 (62.4) | 382 (40.9) | < .0001 | 280 (55.7) | 274 (54.5) | .7 |
| Coronary arterial disease | 239 (31.3) | 88 (9.4) | < .0001 | 79 (15.7) | 83 (16.5) | .7 |
| Congestive heart failure | 38 (5) | 15 (1.6) | < .0001 | 13 (2.6) | 13 (2.6) | 1 |
| Stroke | 39 (5.1) | 35 (3.8) | .2 | 25 (5) | 22 (4.4) | .7 |
| Diabetes | 153 (20) | 80 (8.6) | < .0001 | 75 (14.9) | 71 (14.1) | .7 |
| Statin use (prior 3 mo) | 433 (56.7) | 246 (26.3) | < .0001 | 216 (42.9) | 213 (42.4) | .8 |
| β-Blocker use (prior 3 mo) | 231 (30.2) | 106 (11.4) | < .0001 | 83 (16.5) | 96 (19.1) | .3 |
| Inhaled corticosteroid use (prior 3 mo) | 338 (44.2) | 452 (48.4) | .09 | 235 (46.7) | 247 (49.1) | .4 |
| Long-acting bronchodilator use (prior 3 mo) | .5 | .9 | ||||
| Long-acting muscarinic antagonist (LAMA) | 95 (12.4) | 108 (11.6) | 59 (11.7) | 55 (10.9) | ||
| Long-acting β-agonist (LABA) | 138 (18.1) | 194 20.8) | 97 (19.3) | 106 (21.1) | ||
| Both LAMA and LABA | 199 (26.1) | 249 (26.7) | 132 (26.2) | 134 (26.6) | ||
| Neither LAMA nor LABA | 332 (43.5) | 383 (41) | 215 (42.7) | 208 (41.4) | ||
| Body mass index, mean ± SD | 28.1 ± 5.2 | 26.7 ± 5.2 | < .0001 | 27.8 ± 5.2 | 27.6 ± 5.2 | .5 |
| Underweight (< 18.5 kg/m2) | 18 (2.4) | 42 (4.5) | < .0001 | 13 (2.6) | 12 (2.4) | .9 |
| Normal or overweight (18.5 to < 30 kg/m2) | 474 (62) | 651 (69.7) | 326 (64.8) | 332 (66) | ||
| Obese (≥ 30 kg/m2) | 272 (35.6) | 241 (25.8) | 164 (32.6) | 159 (31.6) | ||
| Propensity score, mean ± SD | 0.57 ± 0.22 | 0.35 ± 0.19 | < .0001 | 0.47 ± 0.18 | 0.47 ± 0.18 | .8 |
MDCT = multidetector row CT; Q1, Q3 = quartiles 1 and 3; SPIROMICS = Subpopulations and Intermediate Outcome Measures in COPD Study.
Boldface entries indicate a statistically significant difference, with a P value less than .05.